Associate Professor Cadilhac |
Monash University researchers from Stroke and Ageing
Research, School of Clinical Sciences at Monash Health, have shown that if
acute stroke care was improved to that of Australian benchmarks, more than 9300
disability-adjusted life years could be avoided every year, at minimal cost to
the health system.
Stroke is a leading cause of death and disability in Australia,
and the associated economic burden is significant.
“The average lifetime
costs of first-ever stroke in Australia is approximately $100,000, comprising
health costs and loss of productivity,” said senior researcher Associate
Professor Dominique Cadilhac.
“While acute stroke treatment guidelines include stroke unit
care, intravenous thrombolysis for patients with ischemic stroke and medication
for secondary prevention, evidence suggests that eligible patients may not
always receive these therapies—even in well-resourced settings.”
The research team estimated the health and economic benefits
from improving standards of care, and converted their results to
disability-adjusted life years (DALYs) avoided.
A DALY is a year of life lost due to illness, disability, or early
death.
“Using 2013 patient data, we estimated that if hospitals had
achieved the benchmark acute stroke care standards, 285 recurrent strokes and
977 deaths or disabilities would have been prevented,” said Dr Joosup Kim who
did the modelling analysis.
“This translates to 9329 DALYs avoided; and these health
benefits could be delivered at an additional cost of $30.8 million or
approximately $3304 per DALY avoided.”
Dr Kim explained that considerable gains in health may be
achieved at relatively low costs by improving the average standard of acute
stroke care in Australia to the standard of top performing hospitals.
“The estimate of $3304 per DALY avoided is considered to be
highly cost effective since the willingness to pay for an additional year of
healthy life is generally accepted as less than the national annual gross
domestic project per capita (approximately $50,000 in Australia).”
The evidence-based therapies included in the research team’s
analysis are already recommended in guidelines, further emphasising the
potential benefits of implementing current knowledge.
“These are benefits that could be achieved with investment
in clinician behaviour change, health service redesign, and support structures
within the clinical setting to attain achievable benchmarks,” said Associate
Professor Cadilhac.
No comments:
Post a Comment